A Research Guide for
Neurofibromatosis Type 1

The First Weeks — A Dated Action Clock

Most NF1 guidance is organized by topic, which is useful for reference and useless at 11pm when you have just been handed a diagnosis and do not know what to do on Monday. This section is organized by when instead.

Within the first week

• Learn the MPNST red flags cold — new or worsening persistent pain (especially pain that wakes you at night), rapid growth, a soft tumor turning hard, new weakness or numbness. This is a fifteen-minute job with the largest payoff in the guide, and it is the one thing that works even before you have a doctor. Teach them to the person with NF1 and to whoever else lives in the house.
• Find out whether an NF specialty center is reachable. The Children's Tumor Foundation's "Find a Doctor" directory (ctf.org; national office (212) 344-6633, toll-free 1-800-323-7938) lists its NF Clinic Network. One search now determines the shape of everything that follows.
• Write down the questions you already have, before they evaporate. The printable appendix at the end of this guide is a starting set — pick the two or three that match your actual situation.
• If any red flag is present right now, this is not a first-week item. Contact your medical team promptly rather than working through this list in order.

Within 2 weeks

• Book the appointment — NF center if reachable, otherwise a clinician willing to follow a written NF surveillance plan. Waiting lists mean booking is the step, not attending.
• Start the one-page medical summary (see Devices & Practical Tools): diagnosis and how it was confirmed, known tumors with locations and last imaging dates, medicines and doses, specialists and numbers, surgeries, allergies. It is the single highest-leverage document in NF1 care and it takes about an hour.
• Photograph any visible or palpable plexiform tumors, dated, from consistent angles, with a ruler or coin in frame for scale. This is the baseline. Its value is entirely in existing before the question of growth ever comes up — a photo taken today cannot be taken retroactively in six months.
• Start the pain log if pain is part of the picture: location, 0–10 score, whether it woke you, any new weakness or numbness. A few lines a week.

Within 3–4 weeks

• Get blood pressure checked — and if it is elevated, ask the specific question rather than accepting a prescription alone.
  Ask: "My blood pressure is high and I have NF1 — have we looked for renal-artery stenosis or a pheochromocytoma?"
• (Young children) Book the ophthalmology appointment if a yearly eye exam is not already scheduled. This is the optic pathway glioma safeguard and it is the most commonly missed item in pediatric NF1 care.
• (Parents) Request the learning/ADHD evaluation if there is any concern at school. Don't wait for failure; waiting lists here are long, and the request is the step.
• (Women approaching or past 30) Raise breast screening. NCCN guidance recommends annual mammography from age 30 with consideration of annual contrast breast MRI ages 30–50. The gap is almost always that it isn't offered, not that it's refused.
  Ask: "NCCN recommends mammograms from 30 and considering breast MRI from 30 to 50 for NF1 — can we arrange both, or refer me to a high-risk breast clinic?"
• If a MEK inhibitor is on the table, this is the window to start the coverage paperwork rather than after the decision is made. Enrollment takes time that is better spent now.

By month 6

• Have a written, personalized surveillance plan in hand — which checks, how often, with which specialist, and what triggers an earlier visit. If your care is local rather than at an NF center, this document is what makes that arrangement work: expert plan, local execution.
• Know your own tumor map. Whether you have plexiform neurofibromas, where they are, and how they are being monitored. "I don't know if I have any" is a common and fixable answer.
• Have a named point of contact and an after-hours route. The red flags are worth nothing if you don't know who to call when one appears at 9pm on a Saturday.
• Address the emotional side if it needs addressing. Six months is long enough to know whether the vigilance is costing you something. It is treatable, and it is part of the condition rather than a soft add-on.
• (If on a MEK inhibitor) The label's monitoring schedule should be on a calendar, not in someone's memory — for selumetinib, an echocardiogram before starting and every 3 months through the first year, per the FDA label.

How NF1 Is Diagnosed

NF1 is usually diagnosed by a doctor recognizing a specific combination of physical features, sometimes confirmed by a genetic test. In 2021, an international group of experts published updated official diagnostic criteria (often called the "Legius 2021" criteria, after the lead author; Genetics in Medicine 2021, PMID 34012067) to make diagnosis more accurate — especially in young children and in people with milder or patchy forms — and to separate NF1 from a look-alike condition called Legius syndrome.

The features doctors look for

In a person who does not have a parent with NF1, a diagnosis generally requires two or more of the following:

• Six or more café-au-lait macules (flat, evenly-brown "coffee-with-milk" spots) larger than 5 mm across before puberty, or larger than 15 mm after puberty.
• Freckling in the armpits or groin (skin folds) — freckles in these hidden areas are more specific to NF1 than face freckles.
• Two or more neurofibromas of any type, or one plexiform neurofibroma (a deeper, more diffuse nerve tumor).
• Optic pathway glioma (a tumor of the vision nerves).
• Two or more Lisch nodules (harmless raised spots on the colored part of the eye, seen with a slit lamp) or two or more choroidal abnormalities (bright patchy spots in the back of the eye, seen with special OCT/infrared imaging) — this eye-imaging option is new in the 2021 criteria and helps diagnose young children.
• A distinctive bone lesion, such as sphenoid dysplasia (a specific skull-bone difference), or bowing/thinning of a long bone such as the tibia (shin), sometimes with pseudarthrosis (a "false joint" where a bone fails to heal).
• A pathogenic change in the NF1 gene, found by genetic testing, present in about half of the body's normal cells.

A child who has a parent with confirmed NF1 needs only one of these features to be diagnosed, because the family history already raises the prior probability substantially.

Genetic testing — when and why

Genetic testing sequences the NF1 gene from a blood sample and looks for a disease-causing change. It is increasingly part of diagnosis, and it is especially useful when:

• Features are few or a child is very young and you want an answer sooner rather than waiting years.
• You need to tell NF1 apart from Legius syndrome, a milder condition (caused by changes in a different gene, SPRED1) that can look identical in early childhood — multiple café-au-lait spots and freckling — but does not cause neurofibromas, optic gliomas, or the other tumor risks. Getting this right changes the entire surveillance plan.
• You are planning a family and want to know the specific change so relatives can be tested or prenatal/preimplantation testing can be considered.
• A specific pattern might predict certain risks (see below).

Ask your doctor: "Would genetic testing change my care or my family's, and can you refer me to a genetic counselor?"

Genetics & What NF1 Can Affect

NF1 is caused by a change in the NF1 gene on chromosome 17, which makes the protein neurofibromin. Neurofibromin normally keeps the RAS growth-signaling pathway in check. With less working neurofibromin, that pathway is more active, which is why cells can over-grow into tumors. This same biology is the reason the MEK-inhibitor medicines work: they block MEK, a step downstream in that pathway, dialing the growth signal back down.

Inheritance — what it means for your family

NF1 is autosomal dominant: a person with NF1 has a 50% chance of passing the gene change to each child, with each pregnancy independent (it is not "one in two children" but "a coin flip each time"). But because NF1 is so variable, a parent and child can be affected very differently — you cannot predict a child's severity from the parent's. About half of all cases are new (de novo) mutations with no family history at all, which is why NF1 regularly appears "out of nowhere."

Ask: "Given our family, what is the chance of passing NF1 on, and what testing options do we have?"

The body systems NF1 can affect

NF1 is a whole-body condition, which is why care draws on many specialties. Here is the landscape; later sections cover management in depth.

• Skin & pigment: café-au-lait spots, skin-fold freckling, and cutaneous neurofibromas (soft bumps that usually appear from the teen years onward — benign, but sometimes numerous and cosmetically or socially distressing).
• Nerves: plexiform neurofibromas (deeper, often present from birth) that can grow, press on structures, and — rarely — turn malignant (MPNST).
• Eyes & vision: optic pathway glioma in young children; Lisch nodules and choroidal changes (harmless in themselves but useful for diagnosis).
• Brain & learning: learning disabilities, ADHD, and autism-spectrum features are common; rarely other brain tumors. Bright "spots" on brain MRI (sometimes called UBOs or FASI) are common and usually harmless.
• Bones: scoliosis, tibial dysplasia (bowing or non-healing of the shin bone), sphenoid wing changes around the eye socket, and lower bone density.
• Blood vessels & blood pressure: narrowed arteries (including of the kidneys, called renal-artery stenosis), aneurysms, and higher rates of high blood pressure.
• Hormones: early or (less often) delayed puberty; rarely a pheochromocytoma (an adrenal tumor that raises blood pressure).
• Growth & build: shorter stature and larger head size are common and usually not a problem in themselves.
• Digestive: uncommonly, tumors of the gut (including a type called GIST) in adults.
• Emotional & social wellbeing: the visible and unpredictable aspects of NF1 can affect mood, self-image, and relationships — a real part of the condition, and treatable.

Managing Tumors & Complications (Including MEK Inhibitors)

Most NF1 tumors are benign, and many need only watching. Treatment is aimed at tumors that cause symptoms, that are growing in a worrying way, or that threaten function — and, urgently, at any tumor suspected of turning malignant. The last few years brought the biggest change in NF1 care in decades: approved medicines that can shrink plexiform neurofibromas.

Understanding the two kinds of neurofibroma

The word "neurofibroma" covers two quite different things:

• Cutaneous (skin) neurofibromas are soft, discrete bumps on or just under the skin. They are benign, do not turn into MPNST, and typically appear from the teen years, often increasing with age and during pregnancy. Their main impact is cosmetic and emotional — which is a legitimate reason to treat them.
• Plexiform neurofibromas grow along nerves in a diffuse, tangled, root-like way. Many are present from early life and grow most in childhood. They can cause pain, disfigurement, and pressure on nearby structures, and they are the tumors that carry the (uncommon) risk of malignant change. These are the tumors the MEK inhibitors target.

MEK inhibitors — the first drugs that shrink plexiform neurofibromas

Because plexiform neurofibromas weave through and around nerves, complete surgical removal is often impossible without damaging the nerve and nearby structures. MEK inhibitors work from the inside, blocking the overactive growth signal at the MEK step of the pathway. Two are now FDA-approved specifically for symptomatic, inoperable plexiform neurofibromas:

Both are taken by mouth every day (capsules, or granules/liquid preparations for young children) over months to years. They shrink many — not all — tumors, and tumors can regrow if the medicine is stopped, so treatment is usually long-term. They are for symptomatic, inoperable plexiform neurofibromas — not for every tumor, not usually for the small skin bumps, and not (outside of research) simply to prevent a stable tumor from growing.

Selumetinib (Koselugo) — the five things worth having on one page

Every figure below comes from the FDA prescribing information for Koselugo (AstraZeneca), as posted on Drugs@FDA and current as of July 2026, except the price, which is sourced separately and marked as such. This is reference information so you can follow the conversation and ask better questions — not a recommendation. Whether this drug fits you, and at what dose, is a decision for your NF team.

• 1. Dose and units. The FDA label specifies 25 mg/m² taken by mouth twice daily. That "per m²" matters: it is a body-surface-area dose calculated from height and weight, not a flat number, which is why two children on "the same drug at the same dose" swallow different amounts — and why the dose is recalculated as a child grows. Supplied as 10 mg and 25 mg capsules, with 5 mg and 7.5 mg oral granules available for young children who cannot swallow capsules.
  Ask: "What is my exact dose in milligrams at today's body surface area, and at what point do you recalculate it?"
• 2. Timing and duration. Per the label, dosing is twice daily and continues until disease progression or unacceptable toxicity. There is no fixed finish line written into the label — no "six cycles and done." That is a genuine feature of this drug class, not an oversight, and it is worth understanding before you start rather than a year in.
  Ask: "What exactly would count as progression or unacceptable toxicity in my case, and how would we detect it?"
• 3. Monitoring — the test and the label's interval. The label directs that ejection fraction (the heart's pumping strength, measured by echocardiogram) be assessed before starting, every 3 months during the first year, then every 6 months thereafter and as clinically indicated. Ophthalmic assessments are directed before starting, at regular intervals during treatment, and for any new or worsening visual change. If creatine phosphokinase (CPK) rises, the label directs evaluation for rhabdomyolysis or other causes. These intervals are the label's, not a suggestion someone invented — which makes them something you can reasonably hold your clinic to.
  Ask: "Can we put the echo and eye-exam dates from the label's schedule into the calendar today, before I leave?"
• 4. Withhold, reduce, or stop — the label's own criteria. The label directs that the drug be withheld, reduced, or permanently discontinued based on the severity of the adverse reaction. Two eye rules are spelled out explicitly: permanently discontinue for retinal vein occlusion (RVO); and withhold for retinal pigment epithelial detachment (RPED), monitor with OCT until it resolves, then resume at a reduced dose. For the liver, the label directs a reduced dose in moderate hepatic impairment (Child-Pugh B) and states that dosage is not established in severe impairment (Child-Pugh C). Note the asymmetry worth knowing in advance: RVO ends treatment permanently, RPED usually pauses it.
  Ask: "Which specific finding would make you withhold this drug, and which one would make you stop it permanently?"
• 5. Cost and the coverage path. As of July 2026, the list price is approximately $2,731 for 28 x 10 mg capsules. AstraZeneca's OneSource CoPay Program states that eligible commercially-insured patients may pay as little as $0, with maximum savings of $26,000 per calendar year; the program line is 1-888-765-4747. Eligibility rules are set by the manufacturer and typically exclude government insurance — the clinic's financial counselor will know how that applies to you. Full detail is in the Cost & Coverage appendix below.
  Ask: "Can your financial counselor enroll me in the manufacturer copay program today?"

Mirdametinib (Gomekli) — the same five fields

Figures from the FDA prescribing information for Gomekli (SpringWorks Therapeutics) on Drugs@FDA, current as of July 2026, with the price sourced separately and marked.

• 1. Dose and units. The label specifies 2 mg/m² by mouth twice daily, with or without food, up to a maximum of 4 mg twice daily. The maximum matters: unlike a pure body-surface-area drug, the dose stops climbing once it hits that ceiling, so a larger adult and a smaller adult may end up on the identical amount. Supplied as 1 mg and 2 mg capsules and as a 1 mg tablet for oral suspension (dispersible), which is the route for those who cannot swallow capsules.
  Ask: "Am I at the 4 mg twice-daily ceiling, or is my dose still being set by body surface area?"
• 2. Timing and schedule — this one is not continuous. This is the single biggest practical difference between the two drugs. The label specifies dosing for the first 21 days of each 28-day cycle — 21 days on, 7 days off, then repeat — continuing until disease progression or unacceptable toxicity. Selumetinib, by contrast, is dosed continuously. A 21/7 cycle is easy to lose track of; a calendar or phone reminder is doing real clinical work here.
  Ask: "Which day of my 28-day cycle am I on today, and what are the dates of my next 7-day break?"
• 3. Monitoring — the test and the interval. The label directs comprehensive ophthalmic assessments before starting treatment, at regular intervals during treatment, and for any new or worsening visual changes or blurred vision. "Regular intervals" is the label's own wording — it does not name a fixed number of months the way the selumetinib cardiac schedule does, which means the actual interval is set by your team rather than read off the label. That is precisely why it is worth pinning down in writing at the start.
  Ask: "The label says eye assessments at regular intervals — what specific interval are you setting for me, and can you write it down?"
• 4. Reduce or stop — what the label and trial report. The label directs continuing until disease progression or unacceptable toxicity. On the tolerability question, the label reports that dose reductions occurred in 17% of adult patients, and that rash was the most common reason for reduction (at a rate of 5% or more). Read that the useful way round: a dose reduction is a common, anticipated event on this drug rather than a sign that treatment has failed — and rash is the thing most likely to trigger it, which is an argument for having the skin-care plan ready before day one rather than after.
  Ask: "If rash forces a dose reduction, what is the reduced dose, and does that change what we expect from the drug?"
• 5. Cost and the coverage path. As of July 2026, the list price is approximately $9,146 for 42 x 1 mg capsules. SpringWorks states that eligible commercially-insured patients may pay as little as $0 per 21-day supply (enrollment line 844-227-3755), and that uninsured or underinsured patients may qualify to receive the medication at no cost through the SpringWorks Patient Assistance Program. That free-drug pathway is the part most often missed — it exists specifically for people who fall outside commercial insurance.
  Ask: "I don't have commercial insurance — can you help me apply to the SpringWorks Patient Assistance Program?"

What "success" looks like — and what it doesn't

It helps to set realistic goals with your team before starting. Shrinkage on MRI is measured carefully (by tumor volume), but the goals that matter most to daily life are functional: less pain, better movement, easier breathing or swallowing, better vision, or improved bladder/bowel function, depending on where the tumor is. Not everyone responds, responses vary in size, and a "good result" may be stabilization plus symptom relief rather than dramatic shrinkage. Knowing this in advance prevents disappointment and helps you and your team judge whether the medicine is earning its place.

Side effects and monitoring for MEK inhibitors

MEK inhibitors are generally manageable, but they need real monitoring — this is not a "take and forget" medicine:

• Skin: an acne-like rash and dry skin are the most common effects, often manageable with gentle skin care and sometimes antibiotics. Sun protection matters.
• Gut: diarrhea, nausea, and sometimes vomiting; usually manageable with dose timing and supportive medicines.
• Heart: the pumping strength of the heart (ejection fraction) is checked with an echocardiogram before starting and periodically afterward, because MEK inhibitors can reduce it — usually reversibly and caught early on monitoring.
• Eyes: rare retina problems can occur — report any new blurring, spots, or vision change promptly; eye checks are part of monitoring.
• Muscle enzyme (CK): a blood muscle marker can rise; report muscle aches or dark urine.
• Nails and hair: nail-fold inflammation (paronychia) and hair thinning can occur.
• Growth and puberty in children: your team monitors growth over time.

Surgery — still essential

Medicines have not replaced surgery; they have joined it. Surgery remains important to:

• Remove or debulk selected neurofibromas that are painful, disfiguring, or pressing on important structures.
• Treat cutaneous neurofibromas (by excision, laser, or electrodessication, often many small ones in one session).
• Address specific complications (for example, orthopedic surgery for scoliosis or tibial pseudarthrosis).
• Urgently remove a tumor suspected of malignant change — here surgery is the main curative treatment.

Plexiform tumors are often only partly removable, and they can regrow, so timing and approach are individualized — ideally at a center with NF and nerve-tumor surgical experience. Sometimes the best plan combines a MEK inhibitor (to shrink a tumor) with later surgery, or surgery first with medicine to manage what remains.

Cancer Risk & MPNST — Plus Treatable Systemic Complications

The great majority of NF1 tumors are benign. But NF1 does raise the risk of a few cancers and of some treatable systemic problems that are easy to miss if no one is looking for them. Knowing about these — and acting on the warning signs — is what turns NF1 from an unpredictable risk into a managed condition.

MPNST — malignant peripheral nerve sheath tumor

An MPNST is a cancer that can arise within a plexiform neurofibroma. Over a lifetime, roughly 8–13% of people with NF1 develop one — most often from adolescence through middle adulthood. It is the most serious NF1-related risk and the leading cause of NF1-related death, which is exactly why the warning signs deserve so much attention. There is currently no approved targeted drug for MPNST; treatment relies on surgery, with radiation and chemotherapy in selected cases — and outcomes depend heavily on catching it early and removing it completely.

Breast cancer in women with NF1

Women with NF1 have a higher risk of breast cancer, particularly before age 50 (studies report roughly a 2–5-fold higher risk under 50, and about 3.5-fold overall), and NF1-associated breast cancers are more often the harder-to-treat, hormone-receptor-negative type, with a somewhat worse prognosis. Because of this, national cancer guidelines (NCCN) recommend:

• Annual mammograms starting at age 30 (a decade earlier than the general population).
• Considering the addition of annual breast MRI with contrast from ages 30 to 50.
• Starting even earlier if breast cancer runs in your family (often 10 years before the youngest relative's diagnosis).

Many women with NF1 are offered mammograms but not the MRI part, and some meet resistance from clinicians unfamiliar with NF1's risk. It is entirely reasonable to bring these guidelines to your appointment or to ask for referral to a high-risk breast clinic, where screening and follow-up are more closely managed.

The vascular & hormone crux — do not miss these

Other cancers — in perspective

NF1 also carries somewhat higher risks of certain other tumors: specific brain tumors (including gliomas beyond the optic pathway), gut tumors called GISTs in adults, certain childhood blood cancers (rare), and, in some studies, a modestly higher overall cancer risk. The everyday message here is not fear but surveillance and warning signs: know your body, keep your scheduled checks, and report changes. Most people with NF1 never develop any of these.

Phase-Based Action Timeline — What to Focus On, by Life Stage

NF1 changes across a lifetime, and so do the priorities. This timeline is a map, not a mandate — your team will tailor it — but it helps you know what usually matters most at each stage, and what to raise at appointments.

Infancy & toddler years (birth to ~3)

• Confirm the diagnosis and, where useful, do genetic testing and see a genetic counselor.
• Establish an NF home base and start the surveillance rhythm.
• Eyes: begin yearly ophthalmology exams (for optic pathway glioma).
• Bones: watch for a bowing lower leg (tibial dysplasia) — act early if present.
• Development: monitor milestones; early intervention if delays appear.
• Blood pressure at visits; document any plexiform tumors.

School age (~4 to 11)

• Learning & attention: screen and, if needed, formally evaluate; set up school supports (504/IEP).
• Eyes: continue yearly exams through about age 8, then as advised.
• Spine: begin watching for scoliosis.
• Puberty: note early/precocious puberty (can signal an optic pathway/hypothalamic issue).
• Plexiform tumors: this is when many grow fastest — monitor symptoms and function; consider a MEK inhibitor if a tumor is symptomatic and inoperable.

Adolescence (~12 to 18)

• Skin neurofibromas often begin — discuss options and emotional impact.
• Scoliosis monitoring continues (curves can progress during growth spurts).
• Mental health & social wellbeing: a key time to support self-image and connection.
• Consider a baseline whole-body MRI in those with high tumor burden, to map internal tumors.
• Begin transition planning toward adult care.

Young & mid adulthood (~18 to 50)

• MPNST vigilance becomes central — know the red flags and act on them.
• Women: breast screening — mammograms from 30, consider MRI 30–50.
• Blood pressure & vascular health; pre-pregnancy evaluation where relevant.
• Family planning and genetic counseling as desired.
• Establish adult NF-literate care if you haven't — a common gap.

Later adulthood (50+)

• Continue MPNST awareness and skin/tumor review.
• General adult health (cardiovascular risk, cancer screening, bone health) alongside NF-specific care.
• Reassess the intensity of screening with your team based on your history.

Detailed Symptom & Complication Management

Beyond tumors, NF1 can bring a set of specific issues, each with its own management. You won't have all of these; use this section as a reference for the ones relevant to you.

Pain

Pain in NF1 has several possible sources — a nerve compressed by a tumor, a skin bump catching on clothing, headaches, orthopedic strain, or (importantly) an early warning of malignant change. The first step is always to distinguish ordinary, stable pain from new, worsening, or night-waking pain, because the latter is a red flag.

The order of operations, and why it is this order. The branch point comes before any treatment: if the pain is new, worsening, or night-waking near a known tumor, imaging is typically considered first, because treating that pain symptomatically is precisely how an early MPNST gets missed — good pain relief can mask the one signal that mattered. Only once a tumor cause has been excluded does the ranked list below apply, roughly ordered by reversibility and evidence:

1. Physical therapy and rehabilitation — first because it is the least invasive and the most reversible, and it is well established for pain, mobility, and function around tumors that affect movement.
2. Nerve-focused pain medicines — where the pain is neuropathic in character rather than mechanical.
3. Targeted procedures — more invasive, and therefore reasonable once the simpler routes have been given a fair trial.
4. Treating the underlying tumor (surgery or a MEK inhibitor) — the most definitive route and the one with the largest commitment attached, which is why it sits at the end rather than the beginning. If a plexiform tumor is symptomatic and inoperable, a MEK inhibitor is typically considered the approved medical option, because that exact combination — symptomatic and not safely removable — is the FDA-approved indication for both drugs.

A pain specialist experienced with nerve pain can be valuable, and unmanaged chronic pain is not something to accept as inevitable.

Ask: "Have we excluded a tumor cause for this pain before we start treating it as ordinary pain?"

Scoliosis and spine

Scoliosis (a sideways curve of the spine) comes in two flavors in NF1. The more common, non-dystrophic type behaves much like ordinary adolescent scoliosis and is monitored and treated similarly (observation, bracing, or surgery depending on the curve). A less common, "dystrophic" type involves abnormal, sometimes rapidly changing bone and may need earlier surgical attention. Regular spine checks in childhood and adolescence catch curves early; report any new asymmetry (uneven shoulders, waist, or a rib hump when bending forward).

Ask: "Is this spine curve the ordinary kind or the dystrophic kind, and how often should we re-check it?"

Tibial dysplasia and bone health

Some infants with NF1 have abnormal shin bone that bows and is prone to fracture and to failing to heal (pseudarthrosis, a "false joint"). This needs early specialist orthopedic care — bracing to protect the bone and, if a fracture or non-union occurs, surgery. A bowing lower leg in a baby or toddler should never be dismissed. Separately, people with NF1 tend to have lower bone density and are often low in vitamin D; simple steps (checking vitamin D, ensuring adequate calcium, weight-bearing activity) support long-term bone health.

Blood pressure and blood vessels

High blood pressure is more common in NF1 and, crucially, more often has a specific cause. In children and young adults especially, narrowing of a kidney artery (renal-artery stenosis) is a leading cause; rarely, a pheochromocytoma is responsible. Both are treatable. The practical rule: high blood pressure in NF1 earns at least one careful evaluation for these causes, not just a prescription. NF1 can also, uncommonly, cause aneurysms or a narrowing of brain arteries (a moyamoya-like pattern), so stroke-like symptoms warrant urgent care.

Ask: "My blood pressure is up and I have NF1 — have we looked for renal-artery stenosis and a pheochromocytoma?"

Learning, attention, and development

Learning disabilities affect a large share of children with NF1, and ADHD is common; autistic traits are also more frequent than average. These are among the most impactful day-to-day aspects of NF1 — and among the most treatable. Early neuropsychological evaluation clarifies strengths and needs; school accommodations (a 504 Plan or IEP in the US) provide support; and ADHD in NF1 generally responds to the same treatments used more broadly. Addressing these early protects a child's confidence and long-term trajectory.

Vision

Optic pathway gliomas are the main vision concern, mostly in young children; many never cause symptoms, and treatment (usually chemotherapy) is reserved for those causing progressive vision loss. What matters is function — how the child actually sees — more than the size on a scan. Regular eye exams, including checks a child can't report themselves, are the safeguard. Report any new squint, head tilt, bumping into objects, or apparent vision change promptly.

Ask your doctor: "How will we track my child's vision when they are too young to read a chart?"

Puberty and growth

Early (precocious) puberty can occur, sometimes signaling a tumor affecting the region near the pituitary/hypothalamus, so it deserves evaluation. Shorter stature and a larger head circumference are common and usually not a problem in themselves. An endocrine specialist can help when puberty or growth seems off-track.

Emotional and social wellbeing

Living with a visible, variable, sometimes uncertain condition takes a toll that is easy to underestimate. Skin bumps, scars, pain, worry about the future, and (for parents) the vigilance itself can affect mood, self-image, relationships, and school or work. This is common and treatable. Counseling, peer support through NF organizations, and connecting with others who understand can be as valuable as any single medical appointment. Seeking help here is not a luxury; it is part of good NF care.

Ask: "Can you refer me to someone who handles the anxiety and body-image side of living with NF1?"

Surveillance — What to Check, and When

Structured, age-based monitoring is the core of NF1 care. The idea is simple: check the things that matter at the ages they matter, so problems are caught early rather than late. Your team will tailor the details, but here is the general shape and the reasoning behind it.

Children

• Yearly NF-focused checkup reviewing skin, growth, development, puberty, blood pressure, spine, and any tumors — ideally with a clinician who knows NF1.
• Yearly eye exam by an ophthalmologist through at least age 7–8 (to catch optic pathway glioma), then as advised.
• Blood pressure at every visit.
• Development and school: screening for learning differences and ADHD, with formal evaluation if concerns arise.
• Spine and legs: watch for scoliosis and for tibial bowing in toddlers.
• Brain MRI is not routine for a symptom-free child — it is used when there are signs (such as vision changes), to avoid unnecessary scans and sedation.

Ask: "Until what age does my child need yearly eye exams, and who does them?"

Teens & adults

• Yearly checkup with a skin exam and a review of any plexiform neurofibromas — specifically asking about new pain, growth, hardening, or neurological changes.
• Blood pressure yearly or more often.
• Women: breast screening as covered above (mammograms from 30; consider MRI 30–50).
• Imaging as indicated: some centers offer a baseline whole-body MRI in adolescence or adulthood to map internal plexiform tumors and set a comparison point — particularly useful with a large tumor burden. This is not universal; ask your center.
• Prompt evaluation of any warning sign — surveillance is not only scheduled visits; it's knowing when to call in between.

Ask: "Should I have a baseline whole-body MRI to map internal tumors, and is it available here?"

Clinical Trials & Emerging Therapy

NF1 research is unusually active right now. Trials are testing newer MEK inhibitors and combinations, treatments for the skin neurofibromas, better approaches for optic pathway glioma, and — a major unmet need — treatments for MPNST, where there is currently no approved targeted drug.

The trials behind today's approved medicines

• Selumetinib (Koselugo): the pediatric approval was based on the SPRINT trial (NCT01362803); the adult approval on the KOMET trial (NCT04924608); and the expansion down to age 1 (with a granule formulation) on the SPRINKLE study (NCT05309668).
• Mirdametinib (Gomekli): the approval was based on the ReNeu trial (NCT03962543).

Naming these helps you read the science behind your own treatment and recognize these trials if you encounter them.

Where the research frontier is

• Optic pathway glioma: multiple studies test MEK inhibitors and other targeted drugs and combinations in children, aiming to preserve vision with fewer side effects than traditional chemotherapy.
• Cutaneous (skin) neurofibromas: a high patient priority — trials are testing topical, injected, and device-based treatments to reduce the burden of skin bumps.
• Plexiform neurofibromas: next-generation MEK inhibitors and combination approaches aim to improve on current response rates and tolerability.
• MPNST: combinations of targeted drugs and immunotherapy are under study. This is an evolving, high-need area without a single breakthrough drug yet — which is exactly why early detection remains so important.

The four trial identifiers behind the approved drugs — as of July 2026

These are the registry numbers you can type directly into ClinicalTrials.gov to read the primary record for the evidence your own treatment rests on. Trial status changes, so these are dated rather than omitted — a number with a date on it is useful; no number at all is not.

All four identifiers are current as of July 2026. Verify current status on ClinicalTrials.gov. A note on reading that table honestly: KOMET's 20% sits next to ReNeu's 41%, and the eye goes straight there. But these are different trials, in different populations, with different designs — KOMET was placebo-controlled, which is a harder test than a single-arm study, and its 5% placebo arm is the number that shows why. Comparing the percentages across rows is not a comparison of the drugs.

Ask: "Which of these trials is the closest match to my situation — my age, my tumor, my symptoms?"

Deciding about a trial — questions of value and honesty

Trials can offer access to promising treatments and expert monitoring, but they also carry uncertainty: the treatment may not work, may have unknown side effects, and may involve extra visits, tests, or travel. A trial is not the same as guaranteed benefit, and standard approved care (including the MEK inhibitors) is often the right choice. Weigh the realistic goals and risks with your team, and ask specifically how a trial compares with your best standard option right now.

Honest evidence status

To keep expectations grounded: MEK inhibitors for symptomatic, inoperable plexiform neurofibromas are approved and evidence-backed. Their use for optic glioma and other situations is promising but largely investigational. MPNST treatment beyond surgery, radiation, and chemotherapy remains an area of active research without an approved targeted drug. Skin-neurofibroma treatments are advancing but still limited. Knowing where each stands helps you tell realistic hope from hype.

Therapies That Have Not Worked (So You Can Recognize the Claims)

You will encounter confident claims — online, from acquaintances, sometimes from well-meaning practitioners. Being able to recognize what rigorous testing has not supported protects your time, money, and safety, and helps you focus energy on what actually helps.

Drugs tried before MEK inhibitors that didn't shrink plexiform tumors

Before MEK inhibitors, researchers tried several targeted drugs for plexiform neurofibromas, and they did not reliably shrink them. Naming them specifically is more useful than a vague warning, because these are the drugs you are most likely to encounter being promoted second-hand:

• Tipifarnib (a farnesyltransferase inhibitor) — tested in a randomized trial for plexiform neurofibroma. The trial was negative. This is the strongest kind of evidence in the list: a randomized design is specifically built to catch a drug that only appears to work, and tipifarnib did not survive it.
• Sirolimus (an mTOR-pathway inhibitor) — did not produce meaningful, durable shrinkage of plexiform neurofibromas.
• Imatinib (a receptor-blocking drug) — did not produce meaningful, durable shrinkage of plexiform neurofibromas.
• Pirfenidone (an anti-fibrotic drug) — did not produce meaningful, durable shrinkage of plexiform neurofibromas.

This history is not trivia. It explains why the MEK inhibitors counted as a genuine breakthrough rather than an incremental step, and it gives you a concrete reason to be skeptical when an older repurposed drug is promoted as a plexiform "treatment" — several already had their turn and did not clear the bar. It is also the honest reason the approved drugs deserve the attention they get: they are the ones that worked where four others did not.

Ask: "Has the treatment you're describing been tested in a randomized trial for plexiform neurofibroma, and what was the result?"

Supplements, herbs, and "natural cures"

No vitamin, herbal product, essential oil, special diet, or supplement has been shown to shrink neurofibromas or change the course of NF1. Claims to the contrary are not supported by rigorous evidence. Beyond simply not working, some supplements can be actively harmful in NF1 because they interfere with prescription medicines — the MEK inhibitors in particular are sensitive to substances that affect the CYP3A liver enzyme, which is why grapefruit and St. John's wort should be avoided on selumetinib. Always tell your team about everything you take.

Other approaches without credible evidence

• "Detox," cleanse, energy, or magnet devices/regimens: no credible evidence in NF1.
• Homeopathy and similar: no evidence of disease-modifying benefit.
• Radiation as a casual treatment for benign tumors: radiation is used carefully and selectively in NF1 because NF1 tissue appears more prone to radiation-induced second tumors and to vascular problems; it is not a routine treatment for benign neurofibromas, and it's specifically avoided where possible in optic pathway glioma.

Devices & Practical Tools

NF1 is a condition where organization is genuinely therapeutic. Because care spans many specialists over decades, and because early detection of change is the core safety task, the humble tools below do real medical work. None of them replaces your care team — but together they make you a far more effective partner in your own surveillance.

The one-page medical summary

If you build only one tool, build this. A single page containing: your diagnosis and how it was confirmed (clinical criteria and/or genetic result), a list of known tumors with locations and last imaging dates, your medicines and doses, your specialists and their contact numbers, your major surgeries, and any allergies. Keep a copy on your phone and a printed copy in your wallet or bag. It transforms emergency-room visits, second opinions, and moves to a new city, and it prevents the exhausting experience of re-explaining a complex history from scratch.

Photo documentation of tumors

Take dated photographs of visible or palpable plexiform tumors and any notable skin lesions, from consistent angles and distances, with a ruler or coin in frame for scale. Repeat every few months, or whenever something feels different. Human memory is poor at judging slow change; photos are not. If a tumor's growth ever becomes a question, a dated photo series is genuinely useful evidence for your team — and it can either raise a legitimate alarm or provide real reassurance.

Symptom and pain diary

Because a change in pain is the most common early sign of malignant transformation, a simple pain log has outsized value. Record: the location, a 0–10 severity score, whether it woke you at night, what makes it better or worse, and any new weakness or numbness. A few lines a week is plenty. What you are looking for is a trend — pain that is steadily escalating, or that has begun waking you — not a single bad day. Bring the log to appointments; "it's worse" is a weak signal, but "it went from 3 to 7 over six weeks and now wakes me twice a night" is a strong one.

Home blood pressure monitor

Given how central blood pressure is in NF1 — and how often high readings have a specific, treatable cause — a validated home cuff is a reasonable investment for many adults with NF1, and for children whose team advises it. Use an appropriately sized cuff (a too-small cuff falsely raises readings), take readings at consistent times while seated and rested, and log them. A pattern of elevated readings is a concrete reason to ask your team about looking for renal-artery stenosis or pheochromocytoma rather than simply adding a pill.

Skin-care kit for MEK-inhibitor rash

If you or your child start a MEK inhibitor, the acne-like rash is common enough that it's worth being ready before it appears rather than scrambling after. Ask your team in advance what they recommend; typically this means gentle non-soap cleansers, a good fragrance-free emollient, diligent sun protection (skin on these drugs is often more sun-sensitive), and a plan for what to do — and whom to call — if the rash becomes severe. Knowing the plan in advance prevents both unnecessary suffering and unnecessary treatment interruptions.

Medication organization

MEK inhibitors are taken long-term, and consistency matters. A weekly pill organizer, a phone alarm, and a refill reminder go a long way. For young children on granules, follow the preparation instructions exactly — some foods and juices interfere with the medicine, so this is one place where improvising is genuinely unwise. Ask the pharmacist to walk you through preparation the first time.

The school and appointment binder

For parents, a single binder (physical or digital) holding evaluations, IEP/504 documents, imaging reports, clinic letters, and a running list of questions makes school meetings and specialist visits dramatically less stressful. Add a page where you jot questions as they occur to you between visits — almost everyone forgets their most important question in the room.

Medical alert identification

For people with significant tumor burden, airway-involving tumors, known vascular disease, or a history of pheochromocytoma, a medical alert bracelet or card noting the NF1 diagnosis and key risks can matter in an emergency — particularly because anesthesia and acute blood-pressure management may need to account for these.

Complementary & Integrative Approaches — A Tiered, Honest Look

Many people with NF1 ask about complementary approaches, and that is entirely reasonable — especially where standard medicine has less to offer (chronic pain, anxiety, fatigue, the emotional weight of the condition). This section is deliberately blunt about what the evidence does and does not support, so you can make choices that help you and avoid ones that could harm you.

How to read the evidence tiers

Throughout this section, approaches are graded by the strength of evidence for the specific use described:

• Tier 1 — Well-supported: good-quality trial evidence, usually for a supportive purpose (not for treating NF1 itself).
• Tier 2 — Reasonable, moderate evidence: supported for a general purpose (e.g., chronic pain) but not studied specifically in NF1; plausible and generally safe.
• Tier 3 — Insufficient evidence / discovery only: promoted or traditionally used, but without evidence of benefit. Use only with caution, transparency with your team, and no expectation of disease benefit.
• Not recommended: lacks evidence and carries meaningful risk.

Tier 1 — Well-supported supportive measures

• Exercise and physical activity. Supports bone density (relevant given lower bone mass in NF1), mood, pain, sleep, and cardiovascular health. Individualize around orthopedic issues (scoliosis, tibial dysplasia) with your team or a physical therapist — but for most people, movement is unambiguously good.
• Physical therapy and rehabilitation. Well-established for pain, mobility, post-surgical recovery, and function around tumors that affect movement.
• Cognitive behavioral therapy (CBT) and related psychological approaches. Strong evidence for chronic pain, anxiety, and depression generally — all of which are common and undertreated in NF1. This is arguably the highest-value "complementary" intervention in the entire section.
• Sleep hygiene and treatment of sleep problems. Poor sleep amplifies pain and mood problems; addressing it pays dividends across the board.
• Vitamin D correction where deficient. Vitamin D deficiency is common in NF1 and bone density is often lower. Correcting a documented deficiency, at doses your clinician recommends, supports bone health. This is bone support — it does not affect tumors.

Tier 2 — Reasonable, moderate evidence (for symptoms, not for NF1)

• Mindfulness-based stress reduction and meditation. Moderate evidence for chronic pain and distress in general populations; safe, and many people with NF1 find it genuinely useful for the vigilance-related anxiety that comes with the condition.
• Acupuncture for chronic pain. Moderate-quality evidence in general chronic-pain populations; not studied specifically in NF1. Reasonable to try for pain after a tumor cause has been excluded. Use a licensed practitioner with sterile technique, and avoid needling directly into tumors or areas of altered sensation without medical guidance.
• Massage and manual therapy. Can help musculoskeletal pain and stress. Caution: avoid deep or aggressive work directly over plexiform tumors, and tell any bodywork practitioner about your condition. Massage should never be used to "work on" a tumor.
• Peer support and patient community. Not a "therapy" in the pharmaceutical sense, but consistently reported as one of the most valuable supports by patients and families.

Tier 3 — Insufficient evidence (and often marketed dishonestly)

• Herbal preparations claimed to shrink tumors (including various traditional-medicine formulations promoted for "tumors" or "nerve health"). No credible evidence of benefit in NF1. Traditional-medicine registries and portals may be legitimate as sources of information about what is used, but the evidence within them for efficacy in NF1 remains unsupported until corroborated by proper trials — and it has not been.
• High-dose antioxidant regimens. No evidence of benefit in NF1, and a theoretical concern that high-dose antioxidants could interfere with certain cancer treatments (chemotherapy, radiation). If you are ever undergoing cancer treatment, do not take these without oncology approval.
• Curcumin/turmeric, green tea extract, and similar "anti-cancer" supplements. Frequently promoted; no evidence of benefit in NF1. Some affect drug metabolism and bleeding risk. Not recommended as NF1 therapy.
• Special diets (ketogenic, alkaline, anti-inflammatory) as NF1 treatments. No evidence they affect tumors or the course of NF1. A generally healthy diet is worthwhile for the usual reasons; framing a diet as NF1 treatment is not supported.
• CBD/cannabis products. Sometimes used for pain. Evidence for chronic pain generally is mixed and modest; no NF1-specific evidence. Important interaction concern: cannabidiol can affect liver enzymes that metabolize other drugs. Discuss with your team, especially on a MEK inhibitor.

Not recommended

• "Detox," chelation, or cleanse protocols: no evidence, real potential for harm.
• Unregulated injectables or products of unknown composition: contamination and adulteration are documented risks in the unregulated supplement market.
• Any product marketed as replacing surveillance, surgery, or approved therapy: this is the most dangerous claim in the field, because the harm comes not from the product but from the delay.

Specialty Center Directory

NF care is best delivered by a multidisciplinary team that sees NF1 regularly. Below are starting points, organized by region. Phone numbers and programs change — always confirm current details before relying on them. Where a number could not be independently confirmed, it is flagged as such inline rather than presented as certain.

Mountain West & Utah

• University of Utah Health — Medical Genetics / NF care (Salt Lake City). Multidisciplinary NF care including medical genetics and genetic counseling, neurology/neuro-oncology, ophthalmology, and orthopedics. University of Utah has historically been an NF Clinical Trials Consortium site. Main hospital line: (801) 581-2121. A published NF research/consortium contact line for the University of Utah program is (801) 587-9017 — verify current clinical intake number.
• Primary Children's Hospital (Salt Lake City). Pediatric neurology, neuro-oncology, ophthalmology, orthopedics, and genetics for children with NF1. Main: (801) 662-1000.
• Huntsman Cancer Institute, University of Utah (Salt Lake City). Sarcoma and MPNST evaluation and treatment; adult neuro-oncology. This is the regional referral point if malignant transformation is ever suspected. Main: (801) 587-7000; cancer information/intake often reached via (888) 424-2100.
• ARUP Laboratories (Salt Lake City). National reference laboratory offering NF1 gene sequencing and deletion/duplication testing (ordered through your clinician). Relevant if you need genetic confirmation, mosaic testing, or family testing.
• Intermountain Health (Utah and surrounding states). Regional pediatric and adult specialty access; useful for local orthopedics, ophthalmology, and primary care coordination alongside an academic NF center.
• Phoenix Children's Hospital NF Clinic (Phoenix, AZ). Nearest large pediatric NF program in the Mountain West/Southwest for families able to travel. Verify current number via the CTF directory.

US National Centers of Excellence

These are among the most established NF programs in the country. Many are NF Clinical Trials Consortium sites, which also means better access to trials.

• Massachusetts General Hospital Neurofibromatosis Clinic (Boston, MA) — one of the oldest and largest NF programs in the US, notable for seeing both adults and children, and a national/international referral center. Appointments: (617) 724-7856.
• Boston Children's Hospital / Harvard Center for NF and Allied Disorders (Boston, MA) — major pediatric NF program. Consortium contact line published as (617) 632-4595; verify current clinic number.
• Children's Hospital of Philadelphia (CHOP) NF Program (Philadelphia, PA) — major pediatric program, strong in optic pathway glioma. (215) 590-7012.
• University of Alabama at Birmingham (UAB) NF Clinic (Birmingham, AL) — major program with deep NF genetics expertise. (205) 934-4983 or (866) 822-4362.
• Washington University in St. Louis / St. Louis Children's (St. Louis, MO) — NF Center with both pediatric and adult NF care. Adult NF appointments have been arranged via email (NFClinic@wustl.edu); verify current number.
• UPMC Children's Hospital of Pittsburgh NF Clinic (Pittsburgh, PA) — (412) 692-5325.
• Seattle Children's Neurofibromatosis Program (Seattle, WA) — (206) 987-2078. Note: some Pacific Northwest programs offer telehealth to neighboring states, which can be valuable for Mountain West families.
• National Cancer Institute (NCI), Pediatric Oncology Branch (Bethesda, MD) — the NCI has been central to NF1 plexiform neurofibroma research, including the SPRINT trial. Relevant for trial access; contact via the NCI or ClinicalTrials.gov.

Other established programs include those at the University of Chicago, Lurie Children's (Chicago), UT Southwestern, Children's Hospital Los Angeles, Vanderbilt, Johns Hopkins, and others. Use the CTF "Find a Doctor" directory for the current list and contact details near you.

Veterans

• George E. Wahlen VA Medical Center (Salt Lake City, UT) — VA care for eligible veterans, with the ability to coordinate with University of Utah academic specialists. Find current contact details via the VA facility locator at va.gov, which is the authoritative source for VA facility numbers.
• VA Community Care. If your VA facility lacks NF expertise (most do — NF1 is uncommon), ask specifically about a Community Care referral to an academic NF center, medical genetics, or a sarcoma center. This is the mechanism by which veterans typically access specialized NF care.
• Service connection. NF1 is a genetic condition, so it is generally not "caused by" service. However, veterans should discuss with a VSO (Veterans Service Officer) whether any aggravation of a pre-existing condition during service, or secondary conditions, may be relevant to their situation. This is a legal/benefits question, not a medical one, and a VSO or accredited representative is the right resource.

Canada

• NF care in Canada is delivered through academic centers within the provincial public systems. Programs affiliated with major university hospitals (including in Toronto, Vancouver, Montreal, and Calgary) provide multidisciplinary NF care. The CTF NF Clinic Network includes Canadian clinics — use the CTF directory to find current listings and numbers.
• Drug coverage note. This is the crucial practical point for Canadian families: whether a MEK inhibitor is funded is determined province by province, and approval by Health Canada does not automatically mean public coverage. Ask the clinic's nurse navigator or social worker early about the coverage pathway, special-access programs, and manufacturer patient-support programs in your province — this process can take time and is best started before you need the drug urgently.
• Canadian high-risk breast screening programs (such as provincial high-risk programs) may accept women with a confirmed NF1 pathogenic variant — ask specifically, as eligibility rules sometimes require a confirmed genetic result rather than a clinical diagnosis alone.

International

• Europe — ERN GENTURIS. The European Reference Network for genetic tumour-risk syndromes coordinates expert care across EU countries and has produced European NF1 surveillance guidance. It is the best starting point for finding an expert center in Europe. CTF also maintains a CTF Europe clinic listing.
• United Kingdom. NF care is delivered through NHS specialist services, with nationally commissioned complex-NF1 services at certain centers. Nerve Tumours UK is the main UK patient organization and provides NF specialist advisor support — a genuinely useful resource for UK families navigating the system.
• Australia / New Zealand. NF programs exist at major children's hospitals (including the Children's Hospital at Westmead in Sydney, which has been an NF Clinical Trials Consortium site). National NF associations can direct you to current services.
• Elsewhere. National NF patient organizations exist in many countries and are typically the fastest route to finding an expert clinician. CTF states it collaborates with clinicians globally and can be contacted for providers in other regions.

International Access & Regulatory Landscape

Which MEK inhibitor is approved, for which ages, and whether it is paid for varies substantially by country. This matters if you move, travel, compare notes with families abroad, or are trying to understand why a treatment available to someone else isn't available to you.

Approvals, age bands, and funding rules change. Treat this table as a starting point and verify with your clinician or your national regulator.

Three divergences worth understanding

• Age bands differ. The US now covers selumetinib from age 1 and in adults; the EU pediatric label began at age 3 and the adult indication came later. So a child who qualifies in one country might not in another — a real source of confusion in international patient communities.
• Breast screening thresholds differ. US guidance (NCCN) recommends mammography from age 30 with consideration of MRI from 30–50. UK practice has historically been more conservative for women under 40 without additional risk factors. If you have NF1 and are told you're "too young" for screening, this transatlantic difference may be why — and it is worth a specific conversation, ideally with a high-risk breast clinic.
• Approval is not the same as access. A drug can be approved and still be unfunded, unavailable locally, or require a special-access application. The practical questions to ask are always: Is it approved here? Is it funded here? Who helps me apply?

Decision Triggers — When to Act, and How Fast

Much of NF1 anxiety comes from not knowing whether something is worth calling about. This section converts the guide's warnings into concrete thresholds. When in doubt, call — NF teams would far rather field a false alarm than miss an early cancer.

Call your NF team within 24–72 hours if:

• New or worsening persistent pain in or near a known plexiform neurofibroma — particularly pain that wakes you at night or is steadily escalating.
• A tumor is growing rapidly or has become noticeably hard or firm.
• New neurological symptoms — weakness, numbness, tingling, or loss of function — in the region of a tumor.
• New vision change in a child, or a new squint, head tilt, or bumping into things.
• On a MEK inhibitor: new vision changes, significant muscle pain or dark urine, severe rash, or severe diarrhea.

Schedule an appointment within a few weeks if:

• Blood pressure readings are consistently elevated.
• A new curve of the spine, uneven shoulders, or a new limp is noticed.
• A child shows signs of early puberty.
• New learning, attention, or behavior concerns emerge at school.
• Skin neurofibromas are causing significant physical or emotional distress.
• You're a woman with NF1 approaching or past age 30 and breast screening hasn't been arranged.
• You're planning a pregnancy or a surgery and haven't had vascular/endocrine evaluation discussed.

Triggers to consider a MEK inhibitor

Discuss with your team when a plexiform neurofibroma is causing symptoms (pain, disfigurement, functional problems, pressure on structures) and cannot be safely and completely removed by surgery. That combination — symptomatic and inoperable — is the approved indication.

Triggers to seek a second opinion or an NF specialty center

• The diagnosis is uncertain, or mosaic/segmental NF1 is suspected.
• Any suspicion of malignant change — always get specialist input before a biopsy or surgery.
• You are being offered surgery on a plexiform tumor and want to know if it's the right call.
• Your local team is unfamiliar with MEK inhibitors or NF1 surveillance.
• You are told screening or treatment "isn't needed" in a way that conflicts with what you've read here — guidelines exist, and you can ask for them to be applied.
• You are transitioning from pediatric to adult care and don't yet have an adult NF-literate clinician.

Top Priorities — If You Can Only Do a Few Things

NF1 care can feel like an endless list. It isn't. If you did only these things, you would capture most of the available benefit. They are ranked roughly by how much they matter.

1. Learn the MPNST red flags and act on them without delay. They are listed in the Quick Start and in Cancer Risk & MPNST; learn them from either. This is the highest-leverage knowledge in the entire guide, because early detection is the single biggest determinant of survival in the most dangerous NF1 complication — and because there is no approved targeted drug to fall back on if it's found late.
2. Establish care with someone who knows NF1. An NF clinic, or at minimum a clinician willing to follow a written NF surveillance plan. Everything else flows from this.
3. Keep the age-appropriate surveillance schedule. Yearly eye exams for young children. Blood pressure at every visit. Developmental screening. Spine checks. Annual review of tumors. These are unglamorous and they are how problems get caught early.
4. Get blood pressure taken seriously. Insist that elevated blood pressure in NF1 gets at least one proper look for renal-artery stenosis and pheochromocytoma — especially before surgery, anesthesia, or pregnancy. This is a treatable, missable, occasionally fatal thing.
5. (Women) Start breast screening at 30 and ask about MRI. The guideline exists; the gap is in it being offered. Ask, and if necessary bring the guideline with you.
6. (Parents) Get learning and attention needs evaluated early. This shapes a child's entire educational and emotional trajectory, and it's among the most treatable aspects of NF1.
7. Ask whether a MEK inhibitor applies to you. If a plexiform tumor is symptomatic and inoperable, there is now a real medical option — one that didn't exist a few years ago. Don't assume your clinician will raise it; ask.
8. Attend to the emotional side. The psychological weight of NF1 is real, common, and treatable. It is not a soft add-on; it substantially determines quality of life.

What We Don't Know Yet

Honesty about uncertainty is part of good medicine, and it helps you interpret conflicting advice. These are real, open questions in NF1 — areas where your doctors are making reasonable judgments rather than following settled evidence. If you get different answers from different specialists on these, that's often why.

Who will develop MPNST — and can we predict it better?

We know some risk factors (large internal tumor burden, whole-gene deletions, atypical nerve-sheath tumors, prior radiation) but we cannot reliably predict which individual will develop an MPNST, or when. Research into blood-based markers (such as circulating tumor DNA) to detect malignant change earlier is promising but not yet standard care. Until that arrives, symptom vigilance and imaging remain the tools we have.

Does whole-body MRI screening actually save lives?

Whole-body MRI can map internal tumors and identify people with high tumor burden. What is not established is whether routine whole-body MRI screening improves survival — and it can generate findings that lead to anxiety, scans, and procedures without clear benefit. This is why practice differs between centers and countries. Reasonable experts disagree; your team's recommendation reflects a judgment call, not a settled fact.

How long should someone stay on a MEK inhibitor?

Tumors can regrow after stopping, but the optimal duration, whether treatment can ever be safely stopped, whether intermittent dosing works, and the very long-term effects of years of MEK inhibition in growing children are all still being worked out. Anyone starting a MEK inhibitor is, in a real sense, at the frontier of what is known — which is a reason for careful monitoring and honest conversations, not a reason to avoid a treatment that clearly helps many people.

Do MEK inhibitors prevent malignant transformation?

This is one of the biggest open questions in the field. It is not established that shrinking a plexiform neurofibroma with a MEK inhibitor reduces the risk that it later becomes an MPNST. Do not assume that being on a MEK inhibitor means you can relax your vigilance about red-flag symptoms. Surveillance continues regardless of treatment.

What's the best treatment for the skin neurofibromas?

Cutaneous neurofibromas are consistently rated by patients as among the most burdensome features of NF1, and yet the treatment options remain limited and largely procedural. Effective topical or systemic treatments are an active research priority and a genuine unmet need.

How do we best support cognition and learning?

Learning difficulties in NF1 are common, but no drug has been convincingly shown to improve the underlying cognitive difficulties (several plausible candidates have been tested without success). The evidence-based approach remains educational support, accommodations, and standard ADHD treatment — which do help.

Other honest gaps

• Optimal surveillance intervals for most complications are based on consensus and reasoning rather than randomized evidence.
• Pregnancy in NF1 is understudied — tumors may grow, blood-pressure risks are elevated, but high-quality guidance is thin.
• Adult NF care is under-developed nearly everywhere, and the transition from pediatric care is a recognized weak point in the system.
• Why the same mutation causes such different disease remains largely unexplained — which is why nobody can tell you with confidence how your NF1 will unfold.

Living Well with NF1

NF1 is lifelong, but for most people it is one part of life rather than its center. This section is about the parts of living with NF1 that medical appointments don't cover — and that often matter just as much.

The psychological reality — named honestly

Two things weigh on people with NF1 that outsiders rarely appreciate. The first is visibility: café-au-lait spots and, especially, skin neurofibromas are on the outside, and other people react to them. The second is uncertainty: a condition where you're taught to watch for cancer warning signs is a condition that asks you to live with a background hum of vigilance. Both are real, both take a toll, and both are treatable. Anxiety, depression, and body-image distress are common in NF1, and they respond to the same effective treatments they respond to in anyone else — therapy, and where appropriate medication. Asking for help here is not weakness or vanity. It is treating a genuine part of the condition.

Work, school, and disability rights

Many people with NF1 work and study without any accommodation at all. Some need adjustments — for pain, fatigue, learning differences, treatment side effects, or appointment schedules. In the US, the Americans with Disabilities Act may entitle you to reasonable workplace accommodations, and children are entitled to educational support through an IEP or 504 Plan. You are not obliged to disclose a diagnosis broadly; disclosure is a personal decision, and it's worth thinking through what you actually need rather than what you feel obliged to explain.

Insurance, cost, and navigation

MEK inhibitors are expensive, surveillance imaging adds up, and multi-specialist care generates a lot of billing. Practical steps: ask your clinic whether they have a nurse navigator, social worker, or financial counselor (many do, and they are underused); ask about manufacturer patient-support programs for the medication; keep records of denials and appeal them, because appeals often succeed; and, if you are told a guideline-recommended screening isn't covered, having the guideline in hand strengthens the appeal.

Ask: "Does this clinic have a nurse navigator or financial counselor who can help with approvals and appeals?"

Exercise, sleep, and everyday health

Ordinary health advice applies, with NF1-specific texture. Exercise supports bone density (lower in NF1), mood, and pain — adapt around orthopedic issues with a physical therapist's guidance rather than avoiding activity altogether. Sleep matters enormously to pain and mood; treat sleep problems rather than enduring them. Blood pressure, not smoking, and cardiovascular health carry extra weight in a condition that affects blood vessels.

Relationships, dating, and disclosure

There is no single right way to talk about NF1 with a partner, friends, or a new relationship. Some people mention it early and matter-of-factly; some wait. What tends to help is having a short, calm, factual explanation ready — a couple of sentences that describe what NF1 is and what it means for you, without either minimizing or catastrophizing. Genetic questions ("could we pass it on?") often arise in serious relationships, and a genetic counselor is a good resource for having that conversation with accurate information rather than fear.

Community

The Children's Tumor Foundation and regional and national NF organizations offer education, clinic directories, financial navigation, and — perhaps most valuably — connection with other people who understand. Many families report that meeting others with NF1 changed their relationship with the condition more than any single appointment did. If you are newly diagnosed and feel isolated, this is a concrete, immediate, no-cost thing you can do.

Children & Family Support

If you are caring for a child with NF1, you are doing two jobs at once: raising a kid, and quietly running a surveillance program in the background. Both matter — and the second must never crowd out the first.

Supporting learning and behavior

• Ask for evaluation if you see reading, math, attention, or social struggles — don't wait for failure. Learning differences and ADHD are common in NF1 and very manageable, and early support prevents the secondary damage to confidence that comes from years of unexplained struggle.
• Use school supports. In the US, ask about a 504 Plan or IEP; bring documentation from your NF team, since many schools have never encountered NF1 and will follow your lead.
• ADHD in NF1 generally responds to the same treatments as ADHD in other children. Discuss options without stigma.
• Watch for the emotional side of learning difficulty — children often internalize struggle as "I'm stupid" long before anyone identifies a learning difference.

Watching for warning signs (without hovering)

This is the hardest balance in NF1 parenting: staying alert without transmitting fear.

• Learn your child's known plexiform tumors and their normal state, so you notice changes: new or worsening pain, faster growth, hardening, or new weakness/numbness.
• Watch vision in the early years: a new squint, head tilt, bumping into things, or "not seeing" — report promptly.
• Watch the spine and legs: a developing curve, uneven shoulders, or a bowing shin in a toddler.
• Keep a note of blood pressure readings; ask that blood pressure be checked at visits.
• Do the watching quietly. Children should not grow up feeling scanned. Age-appropriate honesty ("we check your eyes every year to keep them healthy") is better than either secrecy or a running commentary of worry.

Navigating MEK-inhibitor treatment in a child

• Set expectations early: the medicine shrinks many tumors and often reduces pain, but not all tumors respond, and treatment usually continues long-term.
• Prepare for skin care before the rash appears — it's common, and being ready reduces both distress and treatment interruptions.
• Know the monitoring rhythm: heart echocardiogram, eye checks, blood tests. Put them in the calendar; they are not optional extras.
• Granules for young children can be mixed into yogurt or fruit puree — but follow the instructions exactly, as certain foods and juices interfere with the medicine. Ask the pharmacist to demonstrate.
• Report promptly: new vision changes, significant muscle aches or dark urine, severe diarrhea, or severe rash.
• For teens: discuss contraception frankly if relevant — these drugs can harm a developing baby.

Bones, scoliosis, and orthopedic care

• Scoliosis is monitored and treated by pediatric orthopedics; NF1-related curves can sometimes progress faster than ordinary adolescent curves, so keep the recommended check-ups even when nothing seems to be changing.
• Tibial dysplasia (bowing of the shin) needs specialist care to prevent fracture and non-healing. A bowing lower leg in a toddler is never "just how they're built" — get it looked at.

Siblings and the rest of the family

Siblings of a child with NF1 often absorb a lot: less parental attention, unspoken worry, sometimes their own questions about whether they have it too. Age-appropriate honesty helps, as does dedicated one-on-one time and making it clear they can ask questions. If a sibling might also have NF1, discuss testing and evaluation with your genetics team rather than watching and wondering.

Family genetic planning

• Each child of a parent with NF1 has a 50% chance of inheriting it; severity cannot be predicted from the parent's.
• Genetic counseling can explain testing for siblings and options for future pregnancies (including prenatal and preimplantation testing when the family's specific change is known).
• If your child is the first in the family (a new mutation), your future children are generally at low risk — but a genetic counselor can explain the nuances, including the small possibility of gonadal mosaicism.

Caregiver wellbeing

Parents of children with NF1 carry a specific burden: the vigilance, the appointment load, the fear that they'll miss the sign that mattered. Caregiver anxiety and burnout are common and legitimate. Get your own support — through NF parent communities, counseling, or simply naming it to your clinical team. A depleted parent is not a better guardian, and looking after yourself is part of looking after your child.

Cost & Coverage Appendix — What These Drugs List For, and How People Actually Pay

Cost is the thing patients hit first and guides mention last, usually in the form of "these medicines are expensive." That sentence helps nobody. Below are the actual figures and the actual phone numbers, dated, so you can start the conversation from the same information the billing office has. All figures are as of July 2026 and will drift — the phone numbers are the durable part.

The two list prices side by side (as of July 2026), from the manufacturers' published pricing: selumetinib (Koselugo) is approximately $2,731 for a bottle of 28 x 10 mg capsules; mirdametinib (Gomekli) is approximately $9,146 for 42 x 1 mg capsules. Neither figure is an annual cost, because both are dosed by body size (selumetinib 25 mg/m² twice daily; mirdametinib 2 mg/m² twice daily), so the number of bottles per month depends on the person. On the manufacturers' own copay programs, eligible commercially insured patients may pay as little as $0.

Ask: "Can we confirm today whether I qualify for the $0 copay program, and start the paperwork now?"

Selumetinib (Koselugo, AstraZeneca)

• List price (as of July 2026): approximately $2,731 for 28 x 10 mg capsules. Because the label dose is 25 mg/m² twice daily — a body-surface-area dose — the number of capsules a given person takes varies, so the annual figure varies with body size and cannot be read straight off the price of one bottle.
• Copay program: the OneSource CoPay Program states that eligible commercially-insured patients may pay as little as $0.
• Annual cap: maximum savings of $26,000 per calendar year. Worth noting the cap resets each January — which matters for anyone whose treatment straddles a year boundary.
• Phone: 1-888-765-4747.

Mirdametinib (Gomekli, SpringWorks Therapeutics)

• List price (as of July 2026): approximately $9,146 for 42 x 1 mg capsules. The label schedule is 21 days on, 7 days off in each 28-day cycle, at 2 mg/m² twice daily to a maximum of 4 mg twice daily — so, as with selumetinib, quantity depends on the person and the price of one bottle is not an annual cost.
• Copay program: eligible commercially-insured patients may pay as little as $0 per 21-day supply.
• Phone (enrollment): 844-227-3755.
• Free-drug pathway: uninsured or underinsured patients may qualify to receive the medication at no cost through the SpringWorks Patient Assistance Program. This is the provision most often missed, and it exists precisely for the people the copay program cannot help — if you have no commercial insurance, this is your route, not a dead end.

Eligibility — the honest caveats

• Manufacturer copay programs generally exclude government insurance (such as Medicare and Medicaid) under federal rules. If you are on government insurance, the copay card is typically not the route — ask the financial counselor about foundation grants and the manufacturer's patient assistance pathway instead. The answer is a different door, not no door.
• Eligibility criteria are set by the manufacturer and change. The phone numbers above are the authoritative source; this guide is not.
• "As little as $0" is a ceiling claim, not a promise. What you actually pay depends on your plan's structure and where you are in your deductible.
• Outside the US, none of this applies. Coverage is determined by national or provincial processes — see International Access & Regulatory Landscape. In Canada specifically, funding is decided province by province, and Health Canada approval does not imply coverage.

The costs that aren't the drug

The medication is the visible expense; it is not the only one. Surveillance imaging, the echocardiograms and eye exams the label directs, multi-specialist visits, and travel to an NF center all generate billing, and they continue for years. Two practical points from the Living Well section are worth repeating here because they are where money is actually recovered: ask whether your clinic has a nurse navigator, social worker, or financial counselor; and appeal denials, because appeals often succeed — particularly when a guideline-recommended screening is refused and you can put the guideline itself in front of the reviewer.

Ask: "If this is denied, will you help me write the appeal, and can we cite the NCCN guideline in it?"

What the monitoring and imaging cost — ballpark US figures

These are approximate US list or self-pay ranges as of 2026, meant only to set expectations. Actual charges vary widely by facility, region, and insurance, and an insured patient's share is usually far lower. It is always worth asking for the cash or negotiated price in advance, because imaging centers quote very different numbers for the same scan.

• Screening mammogram: roughly $100 to $250.
• Breast MRI with contrast: roughly $1,000 to $3,000.
• Echocardiogram (the heart scan the selumetinib FDA label requires): roughly $1,000 to $2,000.
• MRI of one region with contrast (for example, to check a plexiform tumor): roughly $1,000 to $3,000.
• Whole-body MRI: roughly $2,000 to $5,000.
• FDG-PET scan (used when malignant change is suspected): roughly $3,000 to $6,000.
• NF1 genetic testing: roughly $250 to $1,000, increasingly covered by insurance for diagnosis and family testing.

Ask: "Can you give me the self-pay price for this scan before I book it, and is a lower-cost imaging center an option?"

For scale on the drug itself: when Gomekli launched in February 2025, SpringWorks estimated average treatment cost at roughly $22,000 per month for children and $30,000 per month for adults — which is exactly why the copay and free-drug programs above exist, and why almost no one pays that figure out of pocket.

Ask your doctor: "Given these costs, which single form should we fill out first to protect me financially?"

Printable Appendix — Questions to Ask Your Doctor

This is the whole guide's question set in one place, grouped by topic, so it can be printed or kept on a phone. Nobody asks all of these. The realistic use is to pick the two or three that match the decision actually in front of you, and to take the answers down in writing. The four highest-leverage decision points — MEK inhibitors, cancer risk, when to act, and caregiving — keep their own question boxes inline in those sections, and the verbatim Ask: scripts scattered through the guide are the exact wording for the moments that matter most.

Glossary

Key References & Sources

This guide draws on the following named sources. For anything that affects your care, confirm the current version with your clinician — approvals and guidelines change.

Diagnostic criteria

• Legius E, Messiaen L, Wolkenstein P, et al.; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021 Aug;23(8):1506–1513. PMID 34012067; doi:10.1038/s41436-021-01170-5.

Approved MEK-inhibitor therapies and their pivotal trials

• Selumetinib (Koselugo, AstraZeneca). FDA approval April 2020 (children ≥2 years); FDA approval September 2025 (granules and capsules, children ≥1 year); FDA approval November 2025 (adults). Indication: NF1 with symptomatic, inoperable plexiform neurofibromas. Full prescribing information via Drugs@FDA.
• SPRINT Phase 2 Stratum 1 trial (pediatric pivotal): NCT01362803 — NCI-sponsored, open-label, single-arm.
• KOMET Phase 3 trial (adult pivotal): NCT04924608 — randomized, double-blind, placebo-controlled.
• SPRINKLE study (oral granule formulation, supporting the age ≥1 expansion): NCT05309668.
• Mirdametinib (Gomekli, SpringWorks Therapeutics; EU: Ezmekly). FDA approval February 11, 2025 for adults and children ≥2 years with NF1 and symptomatic plexiform neurofibromas not amenable to complete resection. EU conditional marketing authorization 2025. Full prescribing information via Drugs@FDA.
• ReNeu Phase 2b trial (pivotal for mirdametinib): NCT03962543 — confirmed overall response rate 41% in adults and 52% in children.

Cancer screening and MPNST

• NCCN Guidelines — Breast Cancer Screening and Diagnosis (NF1: annual mammography from age 30; consider annual breast MRI with contrast ages 30–50) and CNS Cancers (MEK inhibitors for NF1 plexiform neurofibroma).
• NCCN / ESMO sarcoma guidance — principles of MPNST management (surgery with negative margins as the cornerstone; no approved targeted agent).
• Population cohort studies of breast cancer risk and outcomes in women with NF1 (including Nordic register-based cohorts).

Surveillance and management guidance

• ACMG / AAP health-supervision guidance for children with NF1 (annual ophthalmology in young children; blood pressure at every visit; developmental screening; spine monitoring).
• ERN GENTURIS (European Reference Network on genetic tumour-risk syndromes) — European NF1 surveillance guidance, including guidance on whole-body MRI.
• Children's Tumor Foundation and the REiNS International Collaboration — consensus on response criteria, red-flag definitions, and clinical-trial endpoints in NF.

Patient organizations and directories

• Children's Tumor Foundation (ctf.org) — NF Clinic Network "Find a Doctor" directory, NF Registry, patient education. National office: (212) 344-6633; toll-free 1-800-323-7938.
• Neurofibromatosis Network (nfnetwork.org) — US clinic directory.
• Nerve Tumours UK — UK patient organization and NF specialist advisor service.
• ClinicalTrials.gov — primary source for current trials; search "neurofibromatosis type 1."
• MedlinePlus, NCI, and GARD (US National Library of Medicine / National Cancer Institute / NIH) — general patient-facing information.